Siponimod (Mayzent®) is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||03/12/2019|
|Rapid review completed||13/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of siponimod compared with the current standard of care.|